An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats

Cimaglermin (neuregulin 1β3, glial growth factor 2) is a neuregulin growth factor family member in clinical development for chronic heart failure. Previously, in a permanent middle cerebral artery occlusion (pMCAO) rat stroke model, systemic cimaglermin treatment initiated up to 7 days after ischemi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuroscience research 2016-03, Vol.94 (3), p.253-265
Hauptverfasser:	Iaci, Jennifer F., Parry, Tom J., Huang, Zhihong, Pavlopoulos, Elias, Finklestein, Seth P., Ren, Jingmei, Caggiano, Anthony
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis of Variance Animals Axon sprouting Axonal plasticity Behavioral plasticity Brain Infarction - drug therapy Brain Infarction - etiology Cerebral blood flow Data recovery Disease Models, Animal Dosage Dose-Response Relationship, Drug Drug Administration Schedule Functional plasticity Gene Expression Regulation - drug effects Glial plasticity growth factor Growth factors Heart diseases Hemispheres Infarction, Middle Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - physiopathology Intravenous administration Ischemia Male Markers Molecular chains Nerve Tissue Proteins - metabolism Nervous system Neuregulin Neuregulin-1 - therapeutic use Neuronal-glial interactions Neuroplasticity Neuroprotection Occlusion plasticity Proprioception Proteins Rats Rats, Sprague-Dawley Recovery of function Recovery of Function - drug effects Rodents RRID:AB_10374876 RRID:AB_10562420 RRID:AB_10562715 RRID:AB_2107282 RRID:AB_2138153 RRID:AB_2298772 RRID:AB_2313609 RRID:AB_778203 RRID:RGD_734476 Stroke Synapses Synaptogenesis Synaptophysin Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!